US9089570B2ActiveUtilityA1

Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

81
Individually held — no corporate assignee on recordPriority: Sep 3, 2010Filed: Apr 1, 2013Granted: Jul 28, 2015
Est. expirySep 3, 2030(~4.1 yrs left)· nominal 20-yr term from priority
Inventors:Rashida A. Karmali
A61K 31/513A61P 43/00A61K 45/06A61K 31/4192A61P 35/00A61K 2300/00
81
PatentIndex Score
2
Cited by
15
References
19
Claims

Abstract

This invention provides methods and compositions useful for treating early and late stage metastatic cancer to prevent or treat acquired resistance due to gene amplification or mutation in response to chemotherapeutic and/or targeted drugs. In particular, the methods and compositions include carboxiamidotriazole orotate (CTO) alone or in combination with specific regimens of chemotherapeutic and/or targeted drugs designed to overcome the genomic resistance raised to prior therapy.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A pharmaceutical composition of an effective amount of carboxyamidotriazole orotate that prevents or overcomes acquired resistance to chemotherapeutic drugs and targeted drugs due to by gene amplification or mutation, wherein the effective amount of the composition is in the range 50 mg/m 2  to 1500 mg/m 2  based on the patient's body surface. 
     
     
       2. The pharmaceutical composition according to  claim 1 , further comprising one or more chemotherapeutic drugs of choice used in a regimen designed for overcoming acquired drug resistance and treating a cancer selected from the group consisting of breast, colon, head and neck, malignant glioma, glioblastoma, lung, non-small cell lung, melanoma, testicular, gastrointestinal stromal tumor, ovarian, prostate and chronic myeloid leukemia. 
     
     
       3. The pharmaceutical composition according to  claim 1 , further comprising one or more targeted drugs of choice used in a regimen designed for overcoming acquired drag resistance and treating a cancer selected from the group consisting of breast, colon, head and neck, malignant glioma, glioblastoma, lung, non-small cell lung, melanoma, testicular, gastrointestinal stromal tumor, ovarian, prostate and chronic myeloid leukemia. 
     
     
       4. The pharmaceutical composition according to  claim 1 , further comprising a chemotherapeutic drug of choice used in a regimen designed for treating a cancer and a targeted drug of choice used in a regimen designed for overcoming acquired drug resistance and treating a cancer selected from the group consisting of breast, colon, head and neck, malignant glioma, glioblastoma, lung, non-small cell lung, melanoma, testicular, gastrointestinal stromal tumor, ovarian, prostate and chronic myeloid leukemia. 
     
     
       5. The pharmaceutical composition according to  claim 2  wherein the chemotherapeutic is paclitaxel. 
     
     
       6. The pharmaceutical composition of  3  wherein the targeted is erlotinib. 
     
     
       7. The pharmaceutical composition according to  claim 2  wherein the chemotherapeutic drug is carboplatin. 
     
     
       8. The pharmaceutical composition according to  claim 2  wherein the chemotherapeutic drug is premetrexed. 
     
     
       9. The pharmaceutical composition according to  claim 2  wherein the chemotherapeutic drug is docetaxel. 
     
     
       10. The pharmaceutical composition according to  claim 2  wherein the chemotherapeutic drug is lomustine. 
     
     
       11. The pharmaceutical composition according to  claim 2  wherein the chemotherapeutic drug is gemeitabine. 
     
     
       12. The pharmaceutical composition of  claim 3  wherein the targeted drug is cetuximab. 
     
     
       13. The pharmaceutical composition of  claim 3  wherein the targeted drug is panitumumab. 
     
     
       14. The pharmaceutical composition of  claim 3  wherein the targeted drug is imatinib. 
     
     
       15. The pharmaceutical composition of  claim 3  wherein the targeted drug is trastuzumab. 
     
     
       16. The pharmaceutical composition of  claim 3  wherein the targeted drug is bevacizumab. 
     
     
       17. The pharmaceutical composition of  claim 3  wherein the targeted drug is vemurafenib. 
     
     
       18. The pharmaceutical composition of  claim 3  wherein the targeted drug is ipilimumab. 
     
     
       19. The pharmaceutical composition of  claim 3  wherein the targeted drug is tarceva.

Join the waitlist — get patent alerts

Track US9089570B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.